Houssein Safa, MD (@hsafaMD) header
Houssein Safa, MD (@hsafaMD) profile picture

Genitourinary Medical Oncologist @MethodistHosp Neal Cancer Center | via @UTMDAnderson → @MontefioreNYC → @bcmhouston | Views my own

Houston, TX
Joined March 2011
Photo by Houssein Safa, MD (@hsafaMD)Photo by Houssein Safa, MD (@hsafaMD)Photo by Houssein Safa, MD (@hsafaMD)Photo by Houssein Safa, MD (@hsafaMD)Photo by Houssein Safa, MD (@hsafaMD)Photo by Houssein Safa, MD (@hsafaMD)Photo by Houssein Safa, MD (@hsafaMD)Photo by Houssein Safa, MD (@hsafaMD)Photo by Houssein Safa, MD (@hsafaMD)Photo by Houssein Safa, MD (@hsafaMD)
Houssein Safa, MD retweeted
JUST IN: @AmericanCancer (ACS) updates their guidance about routine PSA screening for #prostatecancer, moving off "shared decision-making". This is a major shift since the last ACS recommendations in 2010: 1) High risk (Black men; first-degree relative dx <65 or multiple at any age): annual PSA, ages 45-69 2) Average risk: PSA every 2 years, ages 50–69. American Cancer Society 3) Non-Black men with 1 first-degree relative diagnosed ≥65: PSA every 2 years, ages 45–69. 4) Age 70–74: individualized decision; if screening continues, every 2 years. 5) Age ≥75: generally no screening; very healthy men 75–79 may discuss continued screening. 6) No screening ≥80 and no screening at any age with life expectancy <10 years. @CACancerJournal @DanaFarber_GU @harvardmed @OpenMedInsights Link: acsjournals.onlinelibrary.wi…
4
76
5
227
27,106
Houssein Safa, MD retweeted
Voting for the ASCO Election is now open. I am honored to be running as one of the candidates for the ASCO Board. Visit asco.org/election to learn more about the candidates and place your vote!
28
130
54
303
56,164
Houssein Safa, MD retweeted
3 studies testing Perioperative immune bases therapy (EVP or Gem/Cis/Durva) in muscle invasive bladder all have shown an OS advantage vs standard of care. KN905 (EVP) is distinct in that it’s in a cisplatin ineligible population (accounting for the poor performance of the control arm). It’s also a smaller trial. The control arm of KN-B15 performed slightly better than NIAGARA (Gem/cis for both), but the trials are otherwise similar. The pCR in the EVP trails and the consistent efficacy of EVP is striking. #GU26
1
76
2
170
10,520
Houssein Safa, MD retweeted
The standard of care for MIBC will now include perioperative EVP for both cisplatin eligible and ineligible #BladderCancer pts. The EV304 study presented today @MattGalsky shows an improvement in EFS (HR 0.53) and OS (HR 0.65) for EVP over GC. @ASCO #GU26
2
97
4
197
11,990
Houssein Safa, MD retweeted
KN-B15/EV303: R3 Perioperative EVP vs Gem/cis in MIBC shows EFS HR 0.53 (0.41–0.70), OS HR 0.65 (0.48-0.89), pCR 56% vs 33%, G3+ tox 76% vs 67% #GU26. About half the patients completed 9 cycles of EVP. These are great results. Gem/cid is harder to beat when not all patients are at risk of relapse. Bladder sparing approaches for cCR (~60%) will be where this ends. ‘EVP 1st, ask questions later’. These studies are needed soon.
3
56
4
132
8,057
Houssein Safa, MD retweeted
Truck test passed ✅ #ADCs
In cisplatin-ineligible patients with muscle-invasive bladder cancer, enfortumab vedotin–pembrolizumab plus surgery led to better event-free survival (74.7%, vs. 39.4%) and overall survival (79.7%, vs. 63.1%) than surgery alone at 2 years. Full phase 3 KEYNOTE-905/EV-303 trial results: nej.md/4czl8sG Editorial: Enfortumab Vedotin plus Pembrolizumab as Perioperative Therapy nej.md/4twnv5T
5
19
127
16,941
Houssein Safa, MD retweeted
🎗️Oncology for The Non-Oncologist🎗️ (A practical educational series for internal medicine trainees and physicians) Episode 11: When you hear “small cell carcinoma”, think urgency 🚨. Here’s what you need to do… Listen up - 🧵
4
14
1
52
7,256
Houssein Safa, MD retweeted
🎗️Oncology for The Non-Oncologist🎗️ Episode 11: When you hear “small cell carcinoma”, think urgency 🚨. Here’s what you need to do…
🎗️Oncology for The Non-Oncologist🎗️ (A practical educational series for internal medicine trainees and physicians) Episode 11: When you hear “small cell carcinoma”, think urgency 🚨. Here’s what you need to do… Listen up - 🧵
3
18
3,021
Houssein Safa, MD retweeted
A great cover letter can make or break your manuscript submission. As an editor and author, I've seen how a strong cover letter helps editors grasp your paper’s significance. 🧵 [1/9]
6
87
8
379
74,873
Houssein Safa, MD retweeted
The long awaited thread of all episodes in finally here 👇🏻
🧵- 🩸Hematology for The Non-Hematologist🩸 🎗️Oncology for The Non-Oncologist🎗️ This series reached +1.5M views, +12k likes, & +3k new followers in under 8 weeks. Very Grateful for the support. I put together a collection of all 20 episodes so far in the links below 👇🏻
4
22
2,313
Houssein Safa, MD retweeted
🧵- 🩸Hematology for The Non-Hematologist🩸 🎗️Oncology for The Non-Oncologist🎗️ This series reached +1.5M views, +12k likes, & +3k new followers in under 8 weeks. Very Grateful for the support. I put together a collection of all 20 episodes so far in the links below 👇🏻
11
51
1
212
20,607
Houssein Safa, MD retweeted
1/ Let’s start with a case 72M with metastatic prostate cancer, dx 1y ago, on leuprolide+abiraterone+prednisone w/ regular follow-ups in clinic. In the ED for pneumonia, missed all his home meds. You admit him to medicine & he’s now stable, labs normal. What’s your next move?
26%Stop Abiraterone/pred
16%Send PSA Asap
12%Give leuprolide inpatient
46%Resume Abi/pred
81 votes • Final results
1
1
1
7
3,463
Houssein Safa, MD retweeted
Test your knowledge on prostate cancer.. Check out this poll below with a case study 👇🏻
Replying to @hsafaMD
1/ Let’s start with a case 72M with metastatic prostate cancer, dx 1y ago, on leuprolide+abiraterone+prednisone w/ regular follow-ups in clinic. In the ED for pneumonia, missed all his home meds. You admit him to medicine & he’s now stable, labs normal. What’s your next move?
26%Stop Abiraterone/pred
16%Send PSA Asap
12%Give leuprolide inpatient
46%Resume Abi/pred
81 votes • Final results
1
6
2,066
Houssein Safa, MD retweeted
🎗️Oncology for The Non-Oncologist🎗️ Episode 10: Prostate cancer is very common.. here’s what to do if they get admitted? Link Below 👇
🎗️Oncology for The Non-Oncologist🎗️ (A practical educational series for internal medicine trainees and physicians) Episode 10: Prostate cancer is very common.. here’s what to do if they get admitted? Listen up - 🧵
1
1
15
2,846
Houssein Safa, MD retweeted
🎗️Oncology for The Non-Oncologist🎗️ (A practical educational series for internal medicine trainees and physicians) Episode 10: Prostate cancer is very common.. here’s what to do if they get admitted? Listen up - 🧵
4
23
2
83
11,727
Houssein Safa, MD retweeted
🩸Hematology for The Non-Hematologist🩸 (A practical educational series for internal medicine trainees and physicians) Episode 10: Chronic Myeloid Leukemia… wait, another leukemia? What even is this one? 😵‍💫 Listen up - 🧵
5
40
1
197
27,065
Houssein Safa, MD retweeted
1/ Let’s start with a case 54-year-old man getting a routine CBC: WBC 90k. Diff shows neutrophils, bands, myelocytes, metamyelocytes, basophils, eosinophils, and a few blasts. Patient feels fine. His PCP sends him to the ED. What next test is best for diagnosis?
24%Flow cytometry
37%Bone marrow biopsy
32%BCR-ABL PCR/FISH
6%LDH & uric acid
242 votes • Final results
2
2
1
8
3,608
Houssein Safa, MD retweeted
Great opportunity
🚀 Launching a new series for interns, residents, and hospitalists: 🎗️ Oncology for The Non-Oncologist Tuesdays 🎗️ 🩸 Hematology for The Non-Hematologist Thursdays 🩸 My previous PD used to say “Heme/Onc is like practicing medicine on Mars.” My goal? Take you to Mars, and make it less intimidating. Not to make you a heme/onc specialist, but to give you a practical approach to the heme/onc topics you actually see in internal medicine.
2
4
728
Houssein Safa, MD retweeted
🎗️Oncology for The Non-Oncologist🎗️ (A practical educational series for internal medicine trainees and physicians) Episode 9: Face swelling, neck veins popping 🥵… Don’t forget about SVC syndrome! Listen up - 🧵
5
36
1
179
36,364